American Century Companies Inc. grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,148 shares of the company’s stock after purchasing an additional 2,443 shares during the period. American Century Companies Inc.’s holdings in Neurocrine Biosciences were worth $2,215,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NBIX. Teachers Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 5.6% in the 1st quarter. Teachers Advisors LLC now owns 82,647 shares of the company’s stock worth $3,579,000 after acquiring an additional 4,360 shares during the period. Aperio Group LLC grew its holdings in shares of Neurocrine Biosciences by 3.7% in the 2nd quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock worth $1,027,000 after acquiring an additional 789 shares during the period. Public Employees Retirement Association of Colorado grew its holdings in shares of Neurocrine Biosciences by 98.4% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 284,274 shares of the company’s stock worth $13,077,000 after acquiring an additional 140,981 shares during the period. Grandfield & Dodd LLC grew its holdings in shares of Neurocrine Biosciences by 15.2% in the 2nd quarter. Grandfield & Dodd LLC now owns 6,130 shares of the company’s stock worth $282,000 after acquiring an additional 810 shares during the period. Finally, Sei Investments Co. grew its holdings in shares of Neurocrine Biosciences by 34.6% in the 2nd quarter. Sei Investments Co. now owns 106,389 shares of the company’s stock worth $4,894,000 after acquiring an additional 27,330 shares during the period.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 30,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the transaction, the insider now owns 77,691 shares of the company’s stock, valued at approximately $5,794,194.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Darin Lippoldt sold 9,900 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total value of $723,195.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 150,710 shares of company stock worth $9,758,593. 4.80% of the stock is owned by corporate insiders.

A number of equities research analysts recently weighed in on the company. Oppenheimer Holdings, Inc. set a $85.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, November 14th. Robert W. Baird restated a “buy” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 3rd. Needham & Company LLC restated a “buy” rating and issued a $86.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Barclays PLC upped their price target on Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. Finally, Deutsche Bank AG restated a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $78.88.

Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $71.18 on Monday. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.36. Neurocrine Biosciences had a negative return on equity of 12.88% and a negative net margin of 18.31%. The firm had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same quarter in the prior year, the company earned ($0.43) EPS. equities analysts predict that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current year.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-holdings-boosted-by-american-century-companies-inc/1728591.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.